Summarized by Masters of Longevity from PR Newswire.
Preclinical studies showed potent receptor activity and weight loss in animal models.

Key Takeaways
- ASC30_48 FDC showed greater weight loss versus monotherapies in monkeys.
- ASC48 was a potent GIPR agonist with good oral exposure in NHPs.
- ASC37 had long half-life and reduced weight in rodent and NHP models.



